Starting day 3 @myesmo #ESMO26 w kidney/bladder orals! What a great lineup of trials & speakers — #LITESPARK012 w @DrChoueiri, #LITESPARK011 w @DrDanielHeng, #PEPE w @Iacovelli, phase 1 of XmAb819 w @montypal & AK112 ivonescimab w #JunGuo
@oncoalert
@oncoalert
October 25, 2026 at 7:53 AM
Starting day 3 @myesmo #ESMO26 w kidney/bladder orals! What a great lineup of trials & speakers — #LITESPARK012 w @DrChoueiri, #LITESPARK011 w @DrDanielHeng, #PEPE w @Iacovelli, phase 1 of XmAb819 w @montypal & AK112 ivonescimab w #JunGuo
@oncoalert
@oncoalert
@DrDanielHeng w #LITESPARK011 follow-up — Lenvatinib-belzutifan vs cabozantinib met PFS endpoint and also better for PFS2, just misses on OS. Durable responses. Lenvatinib belzutifan approved in US — another line in the IO refractory setting.
@oncoalert #ESMO26 @myesmo
@oncoalert #ESMO26 @myesmo
October 25, 2026 at 8:07 AM
@DrDanielHeng w #LITESPARK011 follow-up — Lenvatinib-belzutifan vs cabozantinib met PFS endpoint and also better for PFS2, just misses on OS. Durable responses. Lenvatinib belzutifan approved in US — another line in the IO refractory setting.
@oncoalert #ESMO26 @myesmo
@oncoalert #ESMO26 @myesmo
OncoPharm
Lirafugratinib + LITESPARK011
OncoPharm · Episode
open.spotify.com
October 4, 2026 at 2:32 PM
OncoPharm